Every 424B that Abvc Biopharma Inc (ABVC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ABVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABVC filings page.
ABVC BioPharma, Inc. filed a prospectus supplement registering 3,400,187 shares of common stock issuable upon exercise of a common stock purchase warrant, updating its August 7, 2024 prospectus. As of August 10, 2026, ABVC had 26,654,365 common shares outstanding.
For the six months ended June 30, 2026, ABVC generated no revenue and recorded a net loss of $2,500,418, compared with a $3,277,023 loss a year earlier. Cash and cash equivalents were $31,944 versus $681,480 at December 31, 2025, contributing to a working capital deficit of $5,282,776 and operating cash outflows of $1,138,656. The company reports that these conditions raise substantial doubt about its ability to continue as a going concern and plans to rely on improved operations, capital raising and related-party support.
ABVC also describes a planned partial separation of its BioKey Cayman business. It intends to distribute approximately 4,500,000 BioKey Cayman ordinary shares, representing about 15% of BioKey Cayman, pro rata to ABVC shareholders, while retaining roughly 85%. The distribution, originally targeted for August 3, 2026, has been postponed pending tax, administrative and regulatory matters, and no revised date has been set.
ABVC BioPharma, Inc. filed a prospectus supplement covering 225,500 shares of common stock under its existing May 22, 2024 prospectus, while incorporating its Quarterly Report for the period ended June 30, 2026.
For the first six months of 2026, ABVC generated no revenue and recorded a net loss of $2,500,418 and a comprehensive loss of $2,286,585. Cash and cash equivalents declined to $31,944 from $681,480 at year-end 2025, with net cash used in operating activities of $1,138,656. Total assets were $19,400,715 and total liabilities $7,131,155, resulting in total equity of $12,269,560.
The company discloses a working capital deficit of $5,282,776 and states that these conditions, along with continued operating losses and cash outflows, raise substantial doubt about its ability to continue as a going concern. Management plans to seek additional capital through private or public offerings and related-party or shareholder support, and to improve operations to generate positive cash flows. As of August 10, 2026, ABVC had 26,654,365 common shares outstanding.
ABVC BioPharma, Inc. filed a prospectus supplement updating its shelf registration covering 11,714,683 shares of common stock and incorporating its Quarterly Report for the period ended June 30, 2026. The company remains a pre‑revenue biotech focused on plant‑derived drugs and medical devices.
For the six months ended June 30, 2026, ABVC reported a net loss of $2,500,418 and used $1,138,656 in operating cash. Cash and cash equivalents declined to $31,944, and the company had a working capital deficit of $5,282,776, leading management to state that these conditions raise substantial doubt about its ability to continue as a going concern.
Total assets were $19.4 million, including $12.8 million of property and equipment and $2.5 million of long‑term investments. ABVC is also pursuing a partial spin‑off of its BioKey Cayman business, planning to distribute about 15% of BioKey Cayman shares to ABVC shareholders once tax and regulatory issues are resolved.
ABVC BioPharma, Inc. is using this prospectus supplement to register 1,000,000 shares of common stock issuable upon exercise of a common stock purchase warrant, and to incorporate its latest Quarterly Report for the period ended June 30, 2026.
The company reported no revenue, a six‑month net loss of $2.50 million, and operating cash outflows of $1.14 million. Cash and cash equivalents fell to $31,944, with a working capital deficit of $5.28 million, leading management to state that these conditions raise substantial doubt about its ability to continue as a going concern. Total assets were $19.4 million and total liabilities $7.13 million.
ABVC is progressing a planned separation of its BioKey Cayman business, with BioKey Cayman already an Exchange Act reporting company and ABVC intending to distribute about 4,500,000 BioKey Cayman shares (approximately 15% of BioKey Cayman) to ABVC shareholders on a pro rata basis, though the distribution has been postponed.
ABVC BioPharma filed Prospectus Supplement No. 4 to its July 12, 2024 prospectus, registering 1,000,000 shares of common stock underlying a common stock purchase warrant. The supplement also attaches the company’s Q3 2025 Form 10‑Q. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
For the nine months ended September 30, 2025, ABVC reported revenue of $795,950 and a net loss of $4,564,546. The company disclosed a working capital deficit of $2,434,951 and noted substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $192,068 with restricted cash of $661,843. Total assets rose to $21.18 million, reflecting land acquisitions and other noncurrent items.
ABVC BioPharma filed Prospectus Supplement No. 5 updating its April 5, 2024 prospectus covering 11,714,683 shares of common stock. The supplement appends the company’s Form 10-Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and loss from operations was $1,168,410, leading to a net loss attributable to ABVC of $1,246,513. For the nine months, net loss attributable to ABVC was $4,345,610. Cash and cash equivalents were $192,068 with restricted cash of $661,843 as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern, citing a working capital deficit of $2,434,951 and net cash outflows from operating activities of $1,567,264 for the nine months. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
ABVC BioPharma filed Prospectus Supplement No. 5 covering 225,500 shares of common stock and updating its May 22, 2024 prospectus with the company’s Form 10‑Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and net loss attributed to ABVC and subsidiaries was $1,246,513. For the nine months ended September 30, 2025, net loss was $4,564,546. Cash and cash equivalents were $192,068 and restricted cash was $661,843. The filing notes a working capital deficit of $2,434,951 and states there is substantial doubt about the company’s ability to continue as a going concern.
Shares outstanding were 24,301,089 as of October 30, 2025. The company also disclosed restatements affecting 2023 and certain 2024 interim figures, primarily related to stock‑based compensation, convertible note accounting, and noncontrolling interests.